Moderna Named Top Employer by Science for Fifth Consecutive Year
October 24 2019 - 2:21PM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced it has been named one of the global
biopharmaceutical industry’s top employers in Science and Science
Careers’ 2019 Top Employers Survey for the fifth consecutive year.
Moderna was ranked 11th on the list this year.
“Moderna’s recent positive Phase 1 readouts from our
cytomegalovirus vaccine and chikungunya antibody therapeutic show
both the caliber of our science and the relentlessness of our teams
to push forward bold ideas,” said Stéphane Bancel, CEO at Moderna.
“Many thanks to our employees who have helped make Moderna a
Science top employer for five years in a row.”
Since its inception, Moderna has been committed to diversity and
creating an environment where all employees can do their best work.
Each year, the company has added new industry-leading benefits,
including 16 weeks of paid parental leave and 16 weeks of caregiver
leave, a sabbatical program that offers four weeks of paid time off
after five years of full-time employment with the Company, paid
time off for volunteering, and subsidized childcare and public
transit.
The annual employee survey evaluates companies in the
biopharmaceutical industry in categories such as leadership and
direction, work culture and environment, and academic and
intellectual challenge. The Science and Science Careers’ 2019
rankings were based on a total sample of 7,658 respondents. The
vast majority of survey participants came from North America (72%),
Europe (19%) and Asia/Pacific Rim (7%).
About Moderna Moderna is advancing messenger RNA (mRNA)
science to create a new class of transformative medicines for
patients. mRNA medicines are designed to direct the body’s cells to
produce intracellular, membrane or secreted proteins that have a
therapeutic or preventive benefit with the potential to address a
broad spectrum of diseases. Moderna’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing the Company the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense and the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been named a top biopharmaceutical
employer by Science for the past five years. To learn more, visit
www.modernatx.com and connect with us on Twitter, LinkedIn,
Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191024005884/en/
Media: Colleen Hussey Senior Manager, Corporate
Communications 203-470-5620 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024